more good news, page-3

""CVac immunotherapy is an autologous dendritic cell-based cancer therapy based on the same technology as Dendreon?s Provenge. The approval of Provenge for asymptomatic or minimally symptomatic metastatic, hormone-refractory prostate cancer, validates the underlying concept. Like Provenge,, CVac? utilizes activated dendritic cells to stimulate a cellular immune response rather than just an antibody response, which we believe is a key differentiating element resulting in a greater likelihood of success. As CVac? advances through its pivotal trial, the Company will likely gain greater visibility among investors. With success, the upside could be enormous: Dendreon has a market capitalization close to $5 billion following approval of Provenge, approximately 30x greater than Prima BioMed.""

http://www.primabiomed.com.au/investor/